Trial
NCT00384150
Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL)
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Biogen
Collaborators
—
Condition
Lymphoma, Non-Hodgkin's
Intervention
galiximab in combination with rituximab
Why stopped
Enrollment challenges due to changes in standards of care resulted in premature termination. No safety or efficacy events factored into this action.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-11-26